Prelude Capital Management’s Integra LifeSciences IART Stock Holding History

Prelude Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,164	Closed	-$296K	–	1231
2023 Q1	$296K	Buy	+5,164	New	+$291K	0.02%	647
2022 Q3	–	Sell	-5,276	Closed	-$285K	–	1733
2022 Q2	$285K	Buy	+5,276	New	+$317K	0.01%	1091
2020 Q3	–	Sell	-18	Closed	-$1K	–	2060
2020 Q2	$1K	Buy	+18	New	+$885	﹤0.01%	1876
2019 Q1	–	Sell	-149	Closed	-$7K	–	1950
2018 Q4	$7K	Buy	+149	New	+$8.18K	﹤0.01%	1466
2015 Q2	–	Sell	-482	Closed	-$12K	–	1843
2015 Q1	$12K	Buy	+482	New	+$11.4K	﹤0.01%	1810
2014 Q1	–	Sell	-661	Closed	-$13K	–	1985
2013 Q4	$13K	Buy	+661	New	+$12.1K	﹤0.01%	1428

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's IART Position: Q2 2023 in Review

Prelude Capital Management sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 5,164 shares — an estimated $296K sold.

Prelude Capital Management first reported a position in IART in Q4 2013 and held it in 6 quarters. The position peaked at $296K in Q1 2023. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

Prelude Capital Management reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 5,164 Integra LifeSciences shares in Q2 2023, an estimated $296K.
Prelude Capital Management first reported a position in Integra LifeSciences in Q4 2013 and held it in 6 quarters.
Prelude Capital Management's Integra LifeSciences position peaked at $296K in Q1 2023.
283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.